UA93855C2 - Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе - Google Patents

Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе

Info

Publication number
UA93855C2
UA93855C2 UAA200608516A UAA200608516A UA93855C2 UA 93855 C2 UA93855 C2 UA 93855C2 UA A200608516 A UAA200608516 A UA A200608516A UA A200608516 A UAA200608516 A UA A200608516A UA 93855 C2 UA93855 C2 UA 93855C2
Authority
UA
Ukraine
Prior art keywords
neutralizing epitope
growth enhancing
gdf8
based growth
new
Prior art date
Application number
UAA200608516A
Other languages
English (en)
Ukrainian (uk)
Inventor
Девид Э. Джанкер
Марк Д. Коучран
Original Assignee
Шеринг-Плау Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34748944&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA93855(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Шеринг-Плау Лтд. filed Critical Шеринг-Плау Лтд.
Publication of UA93855C2 publication Critical patent/UA93855C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Изобретение обеспечивает новые, специфические антигенные пептиды из белка GDF8. Данное изобретение также обеспечивает слитые белки, которые включают новые пептиды, иммуногены и вакцины на основе новых пептидов и/или слитых белков, антитела, которые специфически связывают новые пептиды GDF8, и способы лечения животных для того, чтобы модулировать активность GDF8, применение вакцин и антител согласно изобретению.
UAA200608516A 2003-12-31 2004-12-21 Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе UA93855C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US53371903P 2003-12-31 2003-12-31

Publications (1)

Publication Number Publication Date
UA93855C2 true UA93855C2 (ru) 2011-03-25

Family

ID=34748944

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200608516A UA93855C2 (ru) 2003-12-31 2004-12-21 Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе

Country Status (21)

Country Link
US (3) US7371726B2 (ru)
EP (1) EP1699820A2 (ru)
JP (2) JP2007535912A (ru)
KR (1) KR20060120229A (ru)
CN (1) CN1902221A (ru)
AR (1) AR047345A1 (ru)
AU (1) AU2004312411B8 (ru)
BR (1) BRPI0418317A (ru)
CA (1) CA2551877A1 (ru)
EC (1) ECSP066683A (ru)
IL (1) IL176494A0 (ru)
MX (1) MXPA06007514A (ru)
NO (1) NO20063478L (ru)
NZ (1) NZ547593A (ru)
PE (1) PE20051050A1 (ru)
RU (1) RU2422460C2 (ru)
SG (1) SG153874A1 (ru)
TW (1) TWI357906B (ru)
UA (1) UA93855C2 (ru)
WO (1) WO2005066204A2 (ru)
ZA (1) ZA200605227B (ru)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9068234B2 (en) * 2003-01-21 2015-06-30 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating gene expression
EP2500437B1 (en) * 2003-01-21 2016-11-30 PTC Therapeutics, Inc. Methods for identifying compounds that modulate untranslated region-dependent gene expression and methods of using same
US8426194B2 (en) * 2003-01-21 2013-04-23 Ptc Therapeutics, Inc. Methods and agents for screening for compounds capable of modulating VEGF expression
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
JP5335239B2 (ja) 2004-09-30 2013-11-06 マイオスティン・セラピューティクス・プロプライエタリー・リミテッド ミオスタチンアイソフォーム
TW200634156A (en) * 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine
JP5052517B2 (ja) * 2005-10-06 2012-10-17 イーライ リリー アンド カンパニー 抗ミオスタチン抗体
UA92504C2 (en) * 2005-10-12 2010-11-10 Эли Лилли Энд Компани Anti-myostatin monoclonal antibody
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
CN101522707B (zh) * 2006-08-03 2013-08-28 莫约斯汀医疗有限公司 肌肉生长抑制素拮抗剂
AU2013231037B2 (en) * 2006-08-03 2016-05-12 Myostin Therapeutics Pty Ltd Myostatin antagonists
EA015916B1 (ru) 2006-09-05 2011-12-30 Эли Лилли Энд Компани Моноклональные антитела к миостатину и их применения
US8283115B1 (en) 2007-06-20 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation
US8283116B1 (en) 2007-06-22 2012-10-09 Ptc Therapeutics, Inc. Methods of screening for compounds for treating spinal muscular atrophy using SMN mRNA translation regulation
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
DK2708559T3 (en) 2008-04-11 2018-06-14 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of repeatedly binding two or more antigen molecules
JO3340B1 (ar) 2010-05-26 2019-03-13 Regeneron Pharma مضادات حيوية لـعامل تمايز النمو 8 البشري
UY33421A (es) * 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
JP2013537425A (ja) 2010-08-16 2013-10-03 アムジエン・インコーポレーテツド ミオスタチンに結合するポリペプチド、組成物および方法
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
EP3597747B1 (en) 2012-08-24 2023-03-15 Chugai Seiyaku Kabushiki Kaisha Mouse fcgammarii-specific fc antibody
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
RS61778B1 (sr) 2013-05-06 2021-06-30 Scholar Rock Inc Kompozicije i postupci za modulaciju faktora rasta
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素ａ之抗體及其用途
CA3005158A1 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
JP6227191B1 (ja) 2014-12-19 2017-11-08 中外製薬株式会社 抗ミオスタチン抗体、変異Ｆｃ領域を含むポリペプチド、および使用方法
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
MA49661A (fr) 2015-04-15 2020-06-03 Regeneron Pharma Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
EP3922645A1 (en) * 2015-09-15 2021-12-15 Scholar Rock, Inc. Anti-pro/latent-myostatin antibodies and uses thereof
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
SI3368069T1 (sl) 2016-06-13 2021-03-31 Scholar Rock, Inc. Uporaba zaviralcev miostatina in kombinirane terapije
JP6527643B2 (ja) 2016-08-05 2019-06-05 中外製薬株式会社 Ｉｌ−８関連疾患の治療用又は予防用組成物
EP4218817A3 (en) 2017-01-06 2023-09-06 Scholar Rock, Inc. Methods for treating metabolic diseases by inhibiting myostatin activation
CN111787981A (zh) 2018-03-01 2020-10-16 瑞泽恩制药公司 改变身体组成的方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977438A (en) 1988-02-26 1999-11-02 Biosource Technologies, Inc. Production of peptides in plants as viral coat protein fusions
CA2014033C (en) * 1989-04-07 1993-02-09 Stephen D. Acres Compositions and treatments for pneumonia in animals
US5422110A (en) * 1991-10-16 1995-06-06 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
WO1993008290A1 (en) * 1991-10-16 1993-04-29 University Of Saskatchewan Enhanced immunogenicity using leukotoxin chimeras
US5994618A (en) * 1997-02-05 1999-11-30 Johns Hopkins University School Of Medicine Growth differentiation factor-8 transgenic mice
US20030074680A1 (en) * 1993-03-19 2003-04-17 Johns Hopkins University School Of Medicine Growth differentiation factor-8
CA2157577C (en) * 1993-03-19 2009-11-17 Se-Jin Lee Growth differentiation factor-8
US6607884B1 (en) * 1993-03-19 2003-08-19 The Johns Hopkins University School Of Medicine Methods of detecting growth differentiation factor-8
US6042832A (en) 1996-08-28 2000-03-28 Thomas Jefferson University Polypeptides fused with alfalfa mosaic virus or ilarvirus capsid proteins
AU6274298A (en) 1997-02-05 1998-08-25 Johns Hopkins University School Of Medicine, The Growth differentiation factor-8
AU746643B2 (en) * 1997-02-05 2002-05-02 Metamorphix International, Inc. Immunization against endogenous molecules
US6656475B1 (en) * 1997-08-01 2003-12-02 The Johns Hopkins University School Of Medicine Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
GB2333706A (en) * 1998-02-02 1999-08-04 Merck & Co Inc Method for increasing muscle mass in animals
US6369201B1 (en) 1998-02-19 2002-04-09 Metamorphix International, Inc. Myostatin multimers
US6004937A (en) * 1998-03-09 1999-12-21 Genetics Institute, Inc. Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
WO1999056768A1 (en) * 1998-05-06 1999-11-11 Metamorphix, Inc. Methods for treating diabetes by inhibiting gdf-8
US6284882B1 (en) * 1999-06-10 2001-09-04 Abbott Laboratories Myostatin gene promoter and inhibition of activation thereof
KR100750695B1 (ko) * 1999-07-20 2007-08-22 파멕사 에이/에스 Ｇｄｆ-8 활성을 하향-조절하는 방법
EP1072680A1 (en) * 1999-07-30 2001-01-31 Pfizer Products Inc. Myostatin regulatory region, nucleotide sequence determination and methods for its use
CA2385186A1 (en) 1999-10-13 2001-04-19 Roswell Park Memorial Institute Induction of a strong immune response to a self-tumor associated antigen
US6730306B1 (en) * 2000-03-08 2004-05-04 Large Scale Biology Corporation Parvovirus vaccine as viral coat protein fusions
US7037501B2 (en) * 2001-01-04 2006-05-02 Regents Of The University Of Minnesota Myostatin immnoconjugate
US7320789B2 (en) * 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
WO2004052930A2 (en) 2002-12-11 2004-06-24 Pharmexa A/S Targeting single epitopes
KR101304718B1 (ko) 2002-12-20 2013-09-05 암겐 인코포레이티드 미오스타틴을 저해하는 결합제
AU2004312411B8 (en) * 2003-12-31 2011-11-24 Schering-Plough Pty. Limited Neutralizing epitope-based growth enhancing vaccine
US20060281075A1 (en) * 2004-12-22 2006-12-14 Large Scale Biology Corporation Purification of viruses, proteins and nucleic acids
TW200634156A (en) 2004-12-30 2006-10-01 Schering Plough Ltd Neutralizing epitope-based growth enhancing vaccine

Also Published As

Publication number Publication date
BRPI0418317A (pt) 2007-05-02
CA2551877A1 (en) 2005-07-21
AU2004312411B2 (en) 2011-11-03
NZ547593A (en) 2009-09-25
MXPA06007514A (es) 2006-08-31
US20080227156A1 (en) 2008-09-18
CN1902221A (zh) 2007-01-24
ECSP066683A (es) 2006-10-25
IL176494A0 (en) 2006-10-05
RU2422460C2 (ru) 2011-06-27
NO20063478L (no) 2006-08-28
SG153874A1 (en) 2009-07-29
TW200526683A (en) 2005-08-16
JP2007535912A (ja) 2007-12-13
WO2005066204A2 (en) 2005-07-21
WO2005066204A3 (en) 2005-08-11
KR20060120229A (ko) 2006-11-24
AU2004312411B8 (en) 2011-11-24
US20050143306A1 (en) 2005-06-30
US20090311282A1 (en) 2009-12-17
US7892561B2 (en) 2011-02-22
US7585648B2 (en) 2009-09-08
EP1699820A2 (en) 2006-09-13
AU2004312411A1 (en) 2005-07-21
AR047345A1 (es) 2006-01-18
PE20051050A1 (es) 2005-12-12
RU2006127314A (ru) 2008-02-10
TWI357906B (en) 2012-02-11
ZA200605227B (en) 2007-03-28
US7371726B2 (en) 2008-05-13
JP2011083290A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
CY1121353T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοi και χρησεις
DE60004496D1 (de) Verwendung von threalose zur stabilisierung von einem flüssigen impfstoff
WO2002080851A3 (en) Chimeric vaccines
HK1125051A1 (en) Virus-like particles as vaccines for paramyxovirus
ATE474048T1 (de) Her2/neu fusionsproteine
DK1355930T3 (da) Fremgangsmåde til identifikation, isolering og fremstilling af antigener mod et specifikt patogen
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
ATE463515T1 (de) Chimaere rekombinante antigene von toxoplasma gondii
BRPI0411854A (pt) veìculos protéicos para vacinas
WO2010074575A3 (en) Recombinant classical swine fever virus (csfv) comprising a modified e2 protein and methods for generating said recombinant csfv.
EP1572087A4 (en) ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
WO2005007673A3 (en) Immunogenic peptides
ATE519784T1 (de) An den humanen igg-fc-rezeptor iib (fcgammariib) bindende substanz
ATE370745T1 (de) Verbesserte polysaccharid- und glykokonjugat- vakzine
TW200634156A (en) Neutralizing epitope-based growth enhancing vaccine
DE60124526D1 (de) Methode zur identifizierung von helicobacter antigenen
DE60222296D1 (de) Impfstoff von umhüllten viren und verfahren zu seiner herstellung
EE200200157A (et) Vaktsiin
DK1208213T3 (da) Fremgangsmåde til fremstilling af proteiner i værtsceller under anvendelse af chaperoniner
GB0409559D0 (en) Polypeptide
EP1578461A4 (en) VACCINES AGAINST HIV TAT PROTEIN FOR GENERATING NEUTRALIZING ANTIBODIES
DE602006018985D1 (de) Zusammensetzung mit einem kolloidalen synthetischen bioresorbierbaren vektor und einem viralen vektor
WO2004047612A3 (en) Methods of therapy and diagnosis